Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Aculys Pharma Launches Japan PIII for Narcolepsy Drug Candidate
November 11, 2022
- KM Biologics’ COVID-19 Vaccine Approval Likely to Delay into FY2023
November 11, 2022
- Opdivo Nabs Japan Drug Sales Throne for 10th Month: Encise
November 11, 2022
- Japan Ethical Drug Sales Up 4.7% in September: Crecon
November 11, 2022
- Mitsubishi Tanabe’s Core Operating Profit Leaps 60.2% in 1st Half on Priority Products, Overseas Sales
November 10, 2022
- Canada Approves Mitsubishi Tanabe’s Oral Edaravone for ALS
November 10, 2022
- My Linh Kha to Become Interim Chief of Amgen Japan
November 10, 2022
- Nichi-Iko Slides into Excess Debt as Hefty Loss Booked by US Unit
November 9, 2022
- Lilly CEO Sees Donanemab’s Accelerated Nod in Coming Months, Japan Approval in 2024
November 9, 2022
- Eisai’s H1 Operating Profit Tanks 91.3% over Pullback from BMS Alliance Gain
November 8, 2022
- Eisai Divests Rights to Myonal, Merislon to Swiss Firm DKSH
November 8, 2022
- Eisai Begins Talks with US, EU, Japan Regulators towards Lecanemab Submissions; CMS Discussion Now Underway
November 8, 2022
- Cartagena Act Stalls Gene Therapy Development in Japan; Pfizer, FIRM Calling for Deregulation
November 7, 2022
- Parexel Sees Japan as Key Market, Envisions FSP as Growth Pillar
November 7, 2022
- Kyowa Kirin’s Revenue Up 11.7% in January-September on Bullish Global Portfolio
November 7, 2022
- Nichi-Iko to Discontinue Sales of 95 Generics Mainly on Quality Issues
November 4, 2022
- Kissei Grants Taiwan Rights for Linzagolix to Synmosa
November 4, 2022
- Moderna Forging Ahead with mRNA Vaccine Programs for Difficult Viruses; CMV, HIV Jabs in Pipeline: CSO
November 4, 2022
- Meiji Pharma Eyes Japan Filing of Arcturus’ COVID Vaccine Next Spring
November 2, 2022
- Takeda Provides Fomepizole to Indonesia to Treat Acute Kidney Injury
November 2, 2022
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…